Search Results - "DE AZAMBUJA, Evandro"

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial by Cameron, David, Prof, Piccart-Gebhart, Martine J, PhD, Gelber, Richard D, PhD, Procter, Marion, PhD, Goldhirsch, Aron, MD, de Azambuja, Evandro, MD, Castro, Gilberto, MD, Untch, Michael, MD, Smith, Ian, MD, Gianni, Luca, MD, Baselga, Jose, MD, Al-Sakaff, Nedal, PhD, Lauer, Sabine, PhD, McFadden, Eleanor, MA, Leyland-Jones, Brian, MBBS, Bell, Richard, MBBS, Dowsett, Mitch, PhD, Jackisch, Christian, MD

“…Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall…”
Get full text

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) by Pestalozzi, Bernhard C, Prof, Holmes, Eileen, PhD, de Azambuja, Evandro, MD, Metzger-Filho, Otto, MD, Hogge, Laurence, MSc, Scullion, Matt, PhD, Láng, István, Prof, Wardley, Andrew, MD, Lichinitser, Mikhail, MD, Sanchez, Roberto I Lopez, MD, Müller, Volkmar, Prof, Dodwell, David, MD, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, Cameron, David, Prof

“…Summary Background Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer. However,…”
Get full text

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives by Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine

“…Achieving a pathologic complete response after neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial demonstrated a…”
Get full text

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment by Nader-Marta, Guilherme, Molinelli, Chiara, Debien, Véronique, Martins-Branco, Diogo, Aftimos, Philippe, de Azambuja, Evandro, Awada, Ahmad

“…Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB)…”
Get full text

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA by Ades, Felipe, Senterre, Christelle, Zardavas, Dimitrios, de Azambuja, Evandro, Popescu, Razvan, Piccart, Martine

“…The development of trastuzumab is considered to be one of the greatest improvements in breast cancer treatment in recent years. This study aims to evaluate…”
Get full text

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer by Ignatiadis, Michail, Zardavas, Dimitrios, Lemort, Marc, Wilke, Celine, Vanderbeeken, Marie-Catherine, D'Hondt, Veronique, De Azambuja, Evandro, Gombos, Andrea, Lebrun, Fabienne, Dal Lago, Lissandra, Bustin, Fanny, Maetens, Marion, Ameye, Lieveke, Veys, Isabelle, Michiels, Stefan, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Nogaret, Jean-Marie, Piccart, Martine, Awada, Ahmad

“…EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in combination with paclitaxel…”
Get full text

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer by von Minckwitz, Gunter, Procter, Marion, de Azambuja, Evandro, Zardavas, Dimitrios, Benyunes, Mark, Viale, Giuseppe, Suter, Thomas, Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Knott, Adam, Lang, Istvan, Levy, Christelle, Yardley, Denise A, Bines, Jose, Gelber, Richard D, Piccart, Martine, Baselga, Jose

“…In this trial, the addition of pertuzumab to trastuzumab and chemotherapy in early-stage HER2-positive breast cancer improved the rate of invasive-disease–free…”
Get full text

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer by Zahavi, Tamar, Salmon-Divon, Mali, Salgado, Roberto, Elkin, Michael, Hermano, Esther, Rubinstein, Ariel M., Francis, Prudence A., Di Leo, Angelo, Viale, Giuseppe, de Azambuja, Evandro, Ameye, Lieveke, Sotiriou, Christos, Salmon, Asher, Kravchenko-Balasha, Nataly, Sonnenblick, Amir

“…Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free…”
Get full text

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives by Ades, Felipe, Zardavas, Dimitrios, Bozovic-Spasojevic, Ivana, Pugliano, Lina, Fumagalli, Debora, de Azambuja, Evandro, Viale, Giuseppe, Sotiriou, Christos, Piccart, Martine

“…Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human…”
Get full text

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer by Agostinetto, Elisa, Eiger, Daniel, Punie, Kevin, de Azambuja, Evandro

“…Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–15% of all breast cancers and it is associated with a poor prognosis…”
Get full text

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer by Pondé, Noam, Ameye, Lieveke, Lambertini, Matteo, Paesmans, Marianne, Piccart, Martine, de Azambuja, Evandro

“…T-DM1 has been approved for the treatment of HER2+ breast cancer. Cardiac dysfunction is a side effect of trastuzumab, a component of T-DM1. However, little is…”
Get full text

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 by LOI, Sherene, SIRTAINE, Nicolas, DE AZAMBUJA, Evandro, QUINAUX, Emmanuel, DI LEO, Angelo, MICHIELS, Stefan, PICCART, Martine J, SOTIRIOU, Christos, PIETTE, Fanny, SALGADO, Roberto, VIALE, Giuseppe, VAN EENOO, Françoise, ROUAS, Ghizlane, FRANCIS, Prudence, CROWN, John P. A, HITRE, Erika

“…Previous preclinical and clinical data suggest that the immune system influences prognosis and response to chemotherapy (CT); however, clinical relevance has…”
Get full text

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status by Lambertini, Matteo, Kroman, Niels, Ameye, Lieveke, Cordoba, Octavi, Pinto, Alvaro, Benedetti, Giovanni, Jensen, Maj-Britt, Gelber, Shari, Del Grande, Maria, Ignatiadis, Michail, de Azambuja, Evandro, Paesmans, Marianne, Peccatori, Fedro A, Azim, Jr, Hatem A

“…Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333…”
Get full text

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer by Saini, Kamal S, Loi, Sherene, de Azambuja, Evandro, Metzger-Filho, Otto, Saini, Monika Lamba, Ignatiadis, Michail, Dancey, Janet E, Piccart-Gebhart, Martine J

“…Summary Alterations of signal transduction pathways leading to uncontrolled cellular proliferation, survival, invasion, and metastases are hallmarks of the…”
Get full text

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy by Franzoi, Maria Alice, Eiger, Daniel, Ameye, Lieveke, Ponde, Noam, Caparica, Rafael, De Angelis, Claudia, Brandão, Mariana, Desmedt, Christine, Di Cosimo, Serena, Kotecki, Nuria, Lambertini, Matteo, Awada, Ahmad, Piccart, Martine, Azambuja, Evandro de

“…Abstract Background There are limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer, especially in patients treated…”
Get full text

How I treat metastatic triple-negative breast cancer by Caparica, Rafael, Lambertini, Matteo, de Azambuja, Evandro

“…Triple-negative breast cancer (TNBC) is associated with a high risk of recurrence and generally a bad prognosis. More than one-third of patients with TNBC will…”
Get full text

Dissecting the Heterogeneity of Triple-Negative Breast Cancer by METZGER-FILHO, Otto, TUTT, Andrew, DI LEO, Angelo, BASELGA, José, SOTIRIOU, Christos, PICCART-GEBHART, Martine, DE AZAMBUJA, Evandro, SAINI, Kamal S, VIALE, Giuseppe, LOI, Sherene, BRADBURY, Ian, BLISS, Judith M, AZIM, Hatem A, ELLIS, Paul

“…Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the…”
Get full text

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response by de Azambuja, Evandro, Dr, Holmes, Andrew P, PhD, Piccart-Gebhart, Martine, MD, Holmes, Eileen, PhD, Di Cosimo, Serena, MD, Swaby, Ramona F, MD, Untch, Michael, MD, Jackisch, Christian, MD, Lang, Istvan, MD, Smith, Ian, MD, Boyle, Frances, MBBS, Xu, Binghe, MD, Barrios, Carlos H, MD, Perez, Edith A, MD, Azim, Hatem A, MD, Kim, Sung-Bae, MD, Kuemmel, Sherko, MD, Huang, Chiun-Sheng, MD, Vuylsteke, Peter, MD, Hsieh, Ruey-Kuen, MD, Gorbunova, Vera, MD, Eniu, Alexandru, MD, Dreosti, Lydia, MD, Tavartkiladze, Natalia, MD, Gelber, Richard D, PhD, Eidtmann, Holger, MD, Baselga, José, MD

“…Summary Background Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib…”
Get full text

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial by Baselga, José, Dr, Bradbury, Ian, PhD, Eidtmann, Holger, MD, Di Cosimo, Serena, MD, de Azambuja, Evandro, MD, Aura, Claudia, MD, Gómez, Henry, MD, Dinh, Phuong, MD, Fauria, Karine, PhD, Van Dooren, Veerle, MSc, Aktan, Gursel, MD, Goldhirsch, Aron, MD, Chang, Tsai-Wang, MD, Horváth, Zsolt, MD, Coccia-Portugal, Maria, MD, Domont, Julien, MD, Tseng, Ling-Min, MD, Kunz, Georg, MD, Sohn, Joo Hyuk, MD, Semiglazov, Vladimir, MD, Lerzo, Guillermo, MD, Palacova, Marketa, MD, Probachai, Volodymyr, MD, Pusztai, Lajos, DPhil, Untch, Michael, PhD, Gelber, Richard D, PhD, Piccart-Gebhart, Martine, PhD

“…Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and…”
Get full text

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis by Salvestrini, Viola, Kim, Kyubo, Caini, Saverio, Alkner, Sara, Ekholm, Maria, Skyttä, Tanja, Becherini, Carlotta, Coles, Charlotte E., Kaidar-Person, Orit, Offersen, Birgitte, de Azambuja, Evandro, Visani, Luca, Cortes, Javier, Harbeck, Nadia, Rugo, Hope S., Isacke, Clare M., Marangoni, Elisabetta, Morandi, Andrea, Lambertini, Matteo, Poortmans, Philip, Livi, Lorenzo, Meattini, Icro

“…•The incidence of symptomatic radionecrosis is higher when combining T-DM1 and brain RT compared to radiotherapy alone.•The combination of T-DM1 and…”
Get full text